Phase 2
1 Year
21 Years
1 Year
21 Years
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
Inclusion Criteria
- children 1-21 years of age
- confirmed diagnosis of measurable solid tumor, including brain tumor, which has
progressed on or after standard therapy, or for which no effective standard therapy
is known
- at least 4 weeks since last dose of immunotherapy, radiotherapy, or chemotherapy
- no more than 3 prior chemotherapies
- no symptomatic brain metastases
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
estimate response rate
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA124-002
NCT ID:
NCT00057473
Start Date:
February 2003
Completion Date:
February 2004
Related Keywords:
- Neoplasms
- unspecified childhood solid tumor, protocol specific
- Neoplasms
Name | Location |
|---|---|
| Local Institution | Fort Lauderdale, Florida |
| Local Institution | Austin, Texas |
